Literature DB >> 22182847

Neurogenic bladder in children: basic principles, new therapeutic trends.

J M Guys1, G Hery, M Haddad, C Borrionne.   

Abstract

Diagnosis of neurogenic bladder is straightforward in children with myelomeningocele. However, recognition is more difficult in patients with occult dysraphism or central nervous system disorders since clinico-anatomical correlations are poor. Careful clinical examination and urodynamic exploration are mandatory for diagnosis and follow-up. Even if urinary leak is the first symptom, the main goal of the pediatric surgeon must be to preserve the upper urinary tract. The ideal protection strategy consists of ensuring that micturition is voluntary and complete and that the bladder capacity is sufficient with adequate compliance and sphincter outlet resistances. Balancing these functions requires a combination of medical and surgical treatment. A variety of techniques can be used depending on gender and age of the patient and social environment. In most cases, intermittent bladder catheterization is necessary to obtain complete evacuation of the bladder. Bladder capacity can be increased by anticholinergic drugs, injection of botulinum toxin into the bladder, and augmentation cystoplasty. Augmentation of bladder outlet resistances requires endoscopic injection of bulking agents, surgical bladder neck reconstruction and urethral lengthening, bladder neck suspension, and artificial urinary sphincter. In difficult cases, continent cystostomy with closure of the bladder neck can achieve definitive continence. At the beginning endoscopic treatment combining anti reflux procedure, injection of the bladder neck and botulinum toxin can be considered as a "total endoscopic management" and should be our first line. Other techniques are under evaluation. Sacral neuro-modulation has given promising results. Artificial tissue engineering will probably be used in the next future. Management of neurogenic bladder is not limited to urological considerations. Orthopedic, digestive, and sexual problems must also be taken into account in order to obtain an "acceptable quality of life".

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22182847     DOI: 10.1177/145749691110000405

Source DB:  PubMed          Journal:  Scand J Surg        ISSN: 1457-4969            Impact factor:   2.360


  8 in total

1.  The performance of silk scaffolds in a rat model of augmentation cystoplasty.

Authors:  Abhishek Seth; Yeun Goo Chung; Eun Seok Gil; Duong Tu; Debra Franck; Dolores Di Vizio; Rosalyn M Adam; David L Kaplan; Carlos R Estrada; Joshua R Mauney
Journal:  Biomaterials       Date:  2013-03-29       Impact factor: 12.479

2.  Bladder tissue regeneration using acellular bi-layer silk scaffolds in a large animal model of augmentation cystoplasty.

Authors:  Duong D Tu; Yeun Goo Chung; Eun Seok Gil; Abhishek Seth; Debra Franck; Vivian Cristofaro; Maryrose P Sullivan; Dolores Di Vizio; Pablo Gomez; Rosalyn M Adam; David L Kaplan; Carlos R Estrada; Joshua R Mauney
Journal:  Biomaterials       Date:  2013-08-13       Impact factor: 12.479

Review 3.  Dynamic reciprocity in cell-scaffold interactions.

Authors:  Joshua R Mauney; Rosalyn M Adam
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

4.  Urinary tract infections in children with myelodysplasia in whom clean intermittent catheterization was administered.

Authors:  Zuhal Albayrak Yıldız; Cengiz Candan; Mustafa Arga; Pınar Turhan; Pınar İşgüven; Müferet Ergüven
Journal:  Turk Pediatri Ars       Date:  2014-03-01

5.  The use of bi-layer silk fibroin scaffolds and small intestinal submucosa matrices to support bladder tissue regeneration in a rat model of spinal cord injury.

Authors:  Yeun Goo Chung; Khalid Algarrahi; Debra Franck; Duong D Tu; Rosalyn M Adam; David L Kaplan; Carlos R Estrada; Joshua R Mauney
Journal:  Biomaterials       Date:  2014-06-07       Impact factor: 12.479

6.  Augmentation Cystoplasty of Diseased Porcine Bladders with Bi-Layer Silk Fibroin Grafts.

Authors:  Saif Affas; Frank-Mattias Schäfer; Khalid Algarrahi; Vivian Cristofaro; Maryrose P Sullivan; Xuehui Yang; Kyle Costa; Bryan Sack; Mehrnaz Gharaee-Kermani; Jill A Macoska; Gokhan Gundogdu; Catherine Seager; Carlos R Estrada; Joshua R Mauney
Journal:  Tissue Eng Part A       Date:  2018-10-26       Impact factor: 3.845

Review 7.  Preventing kidney injury in children with neurogenic bladder dysfunction.

Authors:  Faezeh Javadi Larijani; Mastaneh Moghtaderi; Nilofar Hajizadeh; Farahnak Assadi
Journal:  Int J Prev Med       Date:  2013-12

8.  OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children.

Authors:  Paul F Austin; Israel Franco; Eric Dobremez; Pawel Kroll; Wilson Titanji; Till Geib; Brenda Jenkins; Piet B Hoebeke
Journal:  Neurourol Urodyn       Date:  2020-12-11       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.